Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Haematologica
Asıl Yazarlar: Dimopoulos, Meletios A., San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Sutherland, Heather J., Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, H. Miles, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J., Chari, Ajai, O’Rourke, Lisa, Wu, Kaida, Schecter, Jordan M., Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A. Kate, Khokhar, Nushmia Z., Avet-Loisea, Hervé, Usmani, Saad Z.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6269302/
https://ncbi.nlm.nih.gov/pubmed/30237262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.194282
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller